Amgen Inc Stock (AMGN) Opened Down by 4.69% on May 1: A Full Analysis

AMGN's stock experienced a significant decline today despite the company reporting first-quarter 2026 financial results that largely beat analyst expectations. On April 30th and May 1st, Amgen announced adjusted earnings per share (EPS) of $5.15, exceeding the Zacks Consensus Estimate of $4.73, and total revenues of $8.62 billion, which also surpassed the consensus estimate of $8.47 billion. The company also slightly raised its full-year 2026 revenue and EPS guidance. This positive financial performance was driven by double-digit growth in 16 of its drugs, particularly Repatha, Evenity, and Uplizna, and strong performance from its six key growth drivers. Amgen's investment in research and development, including an increase of 16% year-over-year, indicates a focus on future growth. A key highlight from the earnings call was the expansion of Phase III studies for its investigational obesity and metabolic disease therapy, MariTide, including new switching and maintenance studies.

However, the stock's downturn appears to be largely influenced by other factors that overshadowed the positive earnings report. A significant concern emerged earlier this week when the U.S. Food and Drug Administration (FDA) proposed withdrawing approval of Amgen's autoimmune disease drug, Tavneos. The FDA cited concerns regarding the drug's effectiveness and alleged false statements in the original application. While Amgen is engaging with the agency and has submitted a label amendment for Tavneos, this regulatory uncertainty introduces a notable risk for the company. Additionally, while many drugs showed strong growth, sales of the osteoporosis drug Prolia significantly declined by 34% due to patent expirations and increased competition, missing analyst estimates. The earnings call also introduced a more explicit risk disclosure regarding a draft Notice of Proposed Adjustment (NOPA) from the IRS for 2016-2018, which management stated could have a material financial impact if sustained. This combination of a significant regulatory challenge for an existing drug, underperforming legacy products, and a newly disclosed IRS risk seems to be outweighing the otherwise strong financial beat and positive pipeline updates in the eyes of investors, leading to the observed price movement.

Technically, Amgen Inc (AMGN) shows a MACD (12,26,9) value of [-3.47], indicating a sell signal. The RSI at 47.27 suggests neutral condition and the Williams %R at -45.61 suggests oversold condition. Please monitor closely.

Amgen Inc (AMGN) is in the Pharmaceuticals & Medical Research industry. Its latest annual revenue is $36.75B, ranking 14 in the industry. The net profit is $7.71B, ranking 10 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Hold, with an average price target of $355.59, a high of $432.00, and a low of $200.00.

Company Specific Risks:

• Accelerated sales erosion for key products such as Prolia and Xgeva is anticipated throughout 2026 due to patent expirations and increasing biosimilar competition, as evidenced by a 32% year-over-year decline in combined sales for these products in Q1 2026.
• Regulatory headwinds pose a significant threat to the rare-disease drug Tavneos, with a recent FDA advisory review raising efficacy and data concerns that could lead to proposals for its withdrawal in the U.S.
• Future profitability faces pressure from increasing cost of sales, as higher profit-share, royalty expenses, and shifts in product sales mix are expected to continue impacting margins in upcoming quarters.
• Amgen is experiencing competitive pressures within the high-growth GLP-1 obesity drug market, with its stock underperforming several key rivals over the past month.